Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment

Table 1 Backgrounds of patients without or with history of treatment

	Patients without history of HCC(n=37)	Patients with history of HCC(n=84)	P value
Age (yr)	66.4 ± 9.9	67.0 ± 8.1	NS
Sex (male ∶ female)	32∶5	64∶20	NS
Frequency of positive for anti-HCV	72%	81%	NS
TNM stage (II ∶ III)	12∶25	35∶49	NS
Tumor size (mm)	46.4 ± 23.5	27.7 ± 16.1	P < 0.01
Number of tumors ( ≤3 ∶ >3)	21∶16	23∶61	P < 0.01
Monolobular ∶ bilobular	17∶20	27∶57	NS
Child-Pugh class (A ∶ B)	27∶10	48∶36	NS
Alanine transferase (IU/L)	63.8 ± 45.1	82.1 ± 64.3	P = 0.07
AFP ( ≤100 ∶ >100 ng/mL)	23∶14	53∶31	NS
TAE with or without anti-cancer medication	13∶24	17∶67	NS
Average number of past treatments	-	2.9 ± 2.2	-
History of hepatectomy	-	18%	-
Average observation period (d)	557.6 ± 377.0	493.6 ± 390.6	NS

Anti-HCV: hepatitis C virus antibody; AFP: α-fetoprotein; TNM stage: tumor node metastasis stage.